Enhanced 𝝮3

Fish Oil 805 mg

Yielding:

EPA 320 mg

DHA 185 mg

Capsule (bovine gelatin, glycerin, purified water), sunflower oil, lemon essential oil, natural mixed tocopherols.

Metabolic Benefits

The best evidence for omega-3 supplementation is to help reduce the risk of cardiovascular disease. A 2016 system review assessed the benefit of omega-3 supplementation on triglyceride levels. The analysis used 61 RCTs and 37 longitudinal observational studies to evaluate the current evidence. The REDUCE-IT trial results demonstrated that 4g of EPA ethyl esters (Icosapent Ethyl) could decrease the risk of major ischemic events, including a 20% reduction in cardiovascular death, in patients with elevated TAG level despite being on statin therapy Interestingly, early data from a pilot study by Fortin, S., expect 2.0g of MaxSimil EPA to be equivalent to 4.0 g of Icosapent Ethyl (Vascepa).

Enhanced Ω3 omega fish oils are sourced sustainably from non-GMO and antibiotic free small fish such as sardines, anchovies and mackerel from cold South American deep waters. Furthermore our fish oil is 3rd party certified including a five-star rating under the International Fish Oil Standards™ program (IFOS), sustainable fisheries certification by Friend of the Sea (FOS) and the Marine Stewardship Council (MSC) ensuring the highest purity.

Enhanced O3 coupled with MaxSimil delivery system has been evaluated at great lengths in several Phase I clinical trials. Two human pharmacokinetic studies demonstrated our advanced absorption system is capable of bypassing digestion for rapid absorption and quickly raises blood plasma concentration of omega-3. Brunet S., (2020), demonstrated that compared to control ethyl ester, MaxSimil had 3.14 times greater peak plasma contraction in a 24hr period. Plourde M., (2021) concluded the superior bioavailability of MaxSimil as compared with reconstituted triglyceride (rTG). MaxSimil had 2.1 times greater peak plasma contraction in a 24hr period. Therefore, 1 gram of MaxSimil fish oil will help you reach the same peak plasma contraction versus taking 3 grams of EE fish oil over 4 hours. In the case of rTG, 2 grams of fish oil is needed for every gram of MaxSimil fish oil to reach the same peak blood concentration.

The superior bioavailability of MaxSimil predigested monoglyceride means patients have the potential to achieve optimal omega-3 concentration at a lower serving.

IHN’s Enhanced Ω3 is a patented monoglyceride omega-3 fatty acid researched and developed in Canada. The innovative MaxSimil delivery system was shown to have superior absorption as compared to leading brands of ethyl ester (EE) or reconstituted triglyceride (rTG) fish oils.

The benefits of Omega-3 fatty acids as a food-based therapy are extremely well researched and documented. Clear indications include but are not limited to: cellular anti-oxidation and anti-inflammatory properties. Clinical expertise, documented evidence and patient compliance/value are three key factors crucial in the selection of the appropriate omega 3 fatty acid product.

Most often patient compliance hinges solely on their individual consuming experience. Incomplete digestion of an omega 3 product leading to repeat (fish burp) is a common complaint and a leading factor in poor compliance of fish oil supplementation. Enhanced Ω3 was designed with clinicians and patients in mind; the natural emulsification of Enhanced Ω3 monoglyceride fish oil bypasses the digestive track and facilitatesits absorption into the body.Clinically, Enhanced O3 demonstrated strong absorption properties even in the absence of any digestive enzymes, a 3X greater absorption rate thanstandard ethyl ester or reconstituted triglyceride fish oils and allows for increased patient compliance through modest daily serving requirements.

MaxSimil is a patented delivery system developed by a Canadian professor that allows for the enhanced absorption of lipids into the body. This is achieved by using natural digestive enzymes released by our body; MaxSimil enzymatic process transforms high EPA/DHA fish oils into a monoglyceride emulsion that can be directly absorbed into the intestinal cells bypassing the preliminary stages of digestion.

Vascepa is a pharmaceutical drug derived from fish oil. This omega 3- like pharmaceutical molecule is used as adjunct treatment alongside statin to reduce the risk of cardiovascular risk in adults with elevated triglycerides. The early data from the clinical trial showed the equivalence of 2 grams of Enhanced Ω3 with MaxSimil to that of 4 grams of Vascepa. Lactate threshold is a well-known hindrance for many professional athletes striving to achieve peak performance. Inadequate lactate clearance may be a significant and contributing factor in poor physical performance amongst athletes. An on-going pilot study is evaluating if supplementation with MaxSimil omega-3 can effectively decrease the lactic acid concentration. Early data results suggest a reduction of over 26% in lactic acid with the use of omega 3’s with MaxSimil at maximum physical exertion. These early and promising results provide additional clinical and therapeutic versatility for Enhanced Ω3 with MaxSimil use in clinical practice

• Calder, P. C. (2017). Omega-3 fatty acids and inflammatory processes: from molecules to man. Biochemical Society Transactions, 45(5), 1105–1115. https://doi.org/10.1042/bst20160474
• Anderson, E. J., Thayne, K. A., Harris, M., Shaikh, S. R., Darden, T. M., Lark, D. S., Williams, J. M., Chitwood, W. R., Kypson, A. P., & Rodriguez, E. (2014). Do Fish Oil Omega-3 Fatty Acids Enhance Antioxidant Capacity and Mitochondrial Fatty Acid Oxidation in Human Atrial Myocardium via PPARγ Activation? Antioxidants & Redox Signaling, 21(8), 1156–1163. https://doi.org/10.1089/ars.2014.5888
• Morin, C., Cantin, A., Vézina, F. A., & Fortin, S. (2018). The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine Drugs, 16(6), 184. https://doi.org/10.3390/md16060184
• Chevalier, L., Plourde, M. Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: a randomized controlled trial. Eur J Clin Nutr (2020)
• Morin, C., Rodríguez, E., Blier, P., & Fortin, S. (2017). Potential Application of Eicosapentaenoic Acid Monoacylglyceride in the Management of Colorectal Cancer. Marine Drugs, 15(9), 283. https://doi.org/10.3390/md15090283
• Neptune Wellness Solution (n.d.). Marine Oils. Biodroga Nutraceuticals. Retrieved February 10, 2022, from https://www.biodrogasolutions.com/marine-oils
• Morin, C., Rousseau, R., & Fortin, S. (2013). Anti-proliferative effects of a new docosapentaenoic acid monoacylglyceride in colorectal carcinoma cells. Prostaglandins, Leukotrienes and Essential Fatty Acids, 89(4), 203–213. https://doi.org/10.1016/j.plefa.2013.07.004
• Morin, C., Blier, P. U., & Fortin, S. (2015). Eicosapentaenoic acid and docosapentaenoic acid monoglycerides are more potent than docosahexaenoic acid monoglyceride to resolve inflammation in a rheumatoid arthritis model. Arthritis Research & Therapy, 17(1). https://doi.org/10.1186/s13075-015-0653-y
• Morin, C., Fortin, S., Cantin, A. M., & Rousseau, R. (2011). Docosahexaenoic Acid Derivative Prevents Inflammation and Hyperreactivity in Lung. American Journal of Respiratory Cell and Molecular Biology, 45(2), 366–375. https://doi.org/10.1165/rcmb.2010-0156oc
• Morin, C., Cantin, A., Vézina, F. A., & Fortin, S. (2018). The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine Drugs, 16(6), 184. https://doi.org/10.3390/md16060184
• Morin, C., Cantin, A., Vézina, F. A., & Fortin, S. (2018). The Efficacy of MAG-DHA for Correcting AA/DHA Imbalance of Cystic Fibrosis Patients. Marine Drugs, 16(6), 184. https://doi.org/10.3390/md16060184
• Antonutto G, Di Prampero PE. The concept of lactate threshold. A short review. J Sports Med Phys Fitness. 1995 Mar;35(1):6-12. PMID: 7474995.
• Fortin, S. (in press). mpact of Fish Oil Monoglycerides on the Modulation of Mitochondrial Functions and Lactate Threshold. NIH: ClinicalTrial.Gov.
• Cuenoud, B., Rochat, I., Gosoniu, M., Dupuis, L., Berk, E., Jaudszus, A., Mainz, J., Hafen, G., Beaumont, M., & Cruz-Hernandez, C. (2020). Monoacylglycerol form of omega-3s improves its bioavailability in humans compared to other forms. Nutrients, 12(4), 1014. https://doi.org/10.3390/nu12041014
• Chevalier, L., & Plourde, M. (2020). Comparison of pharmacokinetics of omega-3 fatty acid supplements in monoacylglycerol or ethyl ester in humans: A randomized controlled trial. European Journal of Clinical Nutrition, 75(4), 680–688. https://doi.org/10.1038/s41430-020-00767-4
• Stanton, A. V., James, K., Brennan, M. M., O’Donovan, F., Buskandar, F., Shortall, K., El-Sayed, T., Kennedy, J., Hayes, H., Fahey, A. G., Pender, N., Thom, S. A. M., Moran, N., Williams, D. J., & Dolan, E. (2020). Omega-3 index and blood pressure responses to eating foods naturally enriched with omega-3 polyunsaturated fatty acids: a randomized controlled trial. Scientific Reports, 10(1). https://doi.org/10.1038/s41598-020-71801-5
• Li, Z. H., Zhong, W. F., Liu, S., Kraus, V. B., Zhang, Y. J., Gao, X., Lv, Y. B., Shen, D., Zhang, X. R., Zhang, P. D., Huang, Q. M., Chen, Q., Wu, X. B., Shi, X. M., Wang, D., & Mao, C. (2020). Associations of habitual fish oil supplementation with cardiovascular outcomes and all cause mortality: evidence from a large population based cohort study. BMJ, m456. https://doi.org/10.1136/bmj.m456
• Balk EM, Adam GP, Langberg V, et al. Omega-3 Fatty Acids and Cardiovascular Disease: An Updated Systematic Review. Rockville (MD): Agency for Healthcare Research and Quality (US); 2016 Aug. (Evidence Reports/Technology Assessments, No. 223.) Available from: https://www.ncbi.nlm.nih.gov/books/NBK384547/
• Aung, T., Halsey, J., Kromhout, D., Gerstein, H. C., Marchioli, R., Tavazzi, L., Geleijnse, J. M., Rauch, B., Ness, A., Galan, P., Chew, E. Y., Bosch, J., Collins, R., Lewington, S., Armitage, J., & Clarke, R. (2018). Associations of Omega-3 Fatty Acid Supplement Use With Cardiovascular Disease Risks. JAMA Cardiology, 3(3), 225. https://doi.org/10.1001/jamacardio.2017.5205
• Bhatt DL, Steg PG, Miller M, Brinton EA, Jacobson TA, Ketchum SB, Doyle RT Jr, Juliano RA, Jiao L, Granowitz C, Tardif JC, Ballantyne CM; REDUCE-IT Investigators. Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia. N Engl J Med. 2019 Jan 3;380(1):11-22. doi: 10.1056/NEJMoa1812792. Epub 2018 Nov 10. PMID: 30415628.

IHN’s Enhanced Ω3 is a patented monoglyceride omega-3 fatty acid researched and developed in Canada. The innovative MaxSimil delivery system was shown to have superior absorption as compared to leading brands of ethyl ester (EE) or reconstituted triglyceride (rTG) fish oils. The benefits of Omega-3 fatty acids as a food-based therapy are extremely well researched and documented. Clear indications include but are not limited to: cellular anti-oxidation and anti-inflammatory properties. Clinical expertise, documented evidence and patient compliance/value are three key factors crucial in the selection of the appropriate omega 3 fatty acid product. Most often patient compliance hinges solely on their individual consuming experience. Incomplete digestion of an omega 3 product leading to repeat (fish burp) is a common complaint and a leading factor in poor compliance of fish oil supplementation. Enhanced Ω3 was designed with clinicians and patients in mind; the natural emulsification of Enhanced Ω3 monoglyceride fish oil bypasses the digestive track and facilitates its absorption into the body. Clinically, Enhanced O3 demonstrated strong absorption properties even in the absence of any digestive enzymes, a 3X greater absorption rate than standard ethyl ester or reconstituted triglyceride fish oils and allows for increased patient compliance through modest daily serving requirements.